Study of acute toxicity of the drug «Kolidev 8M» with a single intragastric injection in laboratory animals
DOI:
https://doi.org/10.15587/2519-8025.2021.235952Keywords:
colistin, mice, group, experiment, dose, lethality, autopsy, toxicity, degree of danger, «Kolidev 8M»Abstract
«Kolidev 8M» (powder for oral use) is a veterinary drug used to treat ornamental birds (pheasants, peacocks) in diseases of the digestive tract caused by microorganisms sensitive to colistin.
In the study of the drug «Kolidev 8M» for oral administration, along with the confirmation of therapeutic properties, it is necessary to determine the LD50 obtained in the process of studying acute toxicity.
The aim of research. The aim of research was to determine the acute toxicity of the veterinary drug «Kolidev 8M» (powder for oral administration) under the conditions of intragastric administration to white mice.
Materials and methods of research. To achieve this aim, an experiment was conducted on 114 males of nonlinear white mice kept under optimal conditions in the vivarium of DEVIE LLC (Rivne, Ukraine). In the first series of experiments on the principle of analogues was formed control and three experimental groups of 6 animals each (n=6). The drug in the form of a solution was administered once orally using a esophageal gastric tube in doses of 500,0; 2000,0 and 4000,0 mg/kg body weight by absolute weight of the drug. The animals of the control group were injected with distilled water.
After taking into account the results of the first experiment in the next experiment, 6 experimental groups were formed – mice, which were administered the drug «Kolidev 8M» in the form of a solution in doses (by absolute weight of the drug) – 500,0; 1000,0; 1500,0; 2000.0; 2500,0; 3000,0; 3500 and 4000,0 mg/kg body weight, as well as the control group – animals that were injected with distilled water with a volume of 0.5 cm3 according to similar regulations (Zapadniuk, 1983; Kotsiumbas, 2005; Karkyshchenko & Hrachev, 2010). There were 6 animals in each group (n=6). After their death, a pathological autopsy was performed (Zharov A. et al., 2003).
The average lethal dose of LD50 was calculated by the method of probit analysis by Prozorovsky V.B.
Research results. According to the results of research, it was found that the LD50 of the drug «Kolidev 8M» (powder for oral administration) under the conditions of its single intragastric administration to male mice is 2024,72±232,45 mg/kg, LD10 – 392,87 mg/kg, LD16 – 751,56 mg/kg, LD84 – 3297,88 mg/kg, LD90 – 3656,57 mg/kg, LD100 – 3934,47 mg/kg body weight, respectively.
According to the results of an acute toxicological experiment with intragastric administration of the drug «Kolidev 8M» to white male mice, LD50 was 2024,72±232,45 mg/kg body weight. This allows, according to toxicity, to refer this drug to class IV – low-toxic substances (LD50 501,0-5000,0 mg/kg body weight), and the degree of danger to class III – moderately safe substances (LD50 151,0-5000,0 mg/kg body weight).
Conclusions and prospects for further research. The drug «Kolidev 8M» in terms of toxicity belongs to class IV – low-toxic substances, and the degree of danger to class III – moderately safe substances.
Further studies will be the next stage of pre-registration trials aimed at studying the subacute toxicity of the drug «Kolidev 8M»
References
- Gutyj, B., Grymak, Y., Hunchak, V., Mysak, A., Nazaruk, N., Brezvyn, O. et. al. (2018). Preclinical searches of the preparation Thireomagnile. Ukrainian Journal of Ecology, 8 (1), 688–695. doi: http://doi.org/10.15421/2018_267
- Gutyj, B., Khariv, I., Binkevych, V., Binkevych, O., Levkivska, N., Levkivskyj, D., Vavrysevich, Y. (2017). Research on acute and chronic toxity of the experimental drug Аmprolinsyl. Regulatory Mechanisms in Biosystems, 8 (1), 41–45. doi: http://doi.org/10.15421/021708
- Gutyj, B., Paska, M., Levkivska, N., Pelenyo, R., Nazaruk, N., Guta, Z. (2016). Study of acute and chronic toxicity of ‘injectable mevesel’ investigational drug. Biological Bulletin of Bogdan Chmelnitskiy Melitopol State Pedagogical University, 6 (2), 174–180. doi: http://doi.org/10.15421/201649
- Sachuk, R. M. (2019). Determination of toxicity indicators and assessment of the sensibilizing action of the preparation for the external use “Ointment for wounds.” Journal for Veterinary Medicine, Biotechnology and Biosafety, 5 (3), 22–26. doi: http://doi.org/10.36016/jvmbbs-2019-5-3-5
- Zapadniuk, Y. P., Zapadniuk, V. Y., Zakharyia, E. A., Zapadniuk, B. V. (1983). Laboratornыe zhyvotnыe. Razvedenye, soderzhanye, yspolzovanye v эksperymente. Kyiv: Vyshcha shkola, 383.
- Kotsiumbas, I. Ya., Malyk, O. H., Patereha, I. P. et. al.; Kotsiumbas, I. Ya. (Ed.) (2006). Doklinichni doslidzhennia veterynarnykh likarskykh zasobiv. Lviv: Triada plius, 360.
- Karkischenko, N. N., Grachev, S. V. (2010). Rukovodstvo po laboratornym zhivotnym i alternativnym modelyam v biomeditsinskikh tekhnologiyakh. Moscow: Profil, 358.
- Zharov, A. V., Ivanov, I. V., Strelnikov, A. P. (2003). Vskrytie i patomorfologicheskaya diagnostika bolezney zhivotnykh. Kyiv: Kolos, 400.
- Prozorovskiy, V. B. (2007). Statisticheskaya obrabotka rezultatov farmakologicheskikh issledovaniy. Psikhofarmakologiya i biologicheskaya narkologiya, 7 (3-4), 2090–2120.
- Parshina, V. I., Abramov, V. E. (2010). Farmakodinamika i vliyanie na kachestvo produktov uboya inektsionnoy lekarstvennoy formy enrofloksatsina s kolistinom. Veterinarnaya patologiya, 4, 72–75.
- Nation, R. L., Li, J. (2009). Colistin in the 21st century. Current Opinion in Infectious Diseases, 22 (6), 535–543. doi: http://doi.org/10.1097/qco.0b013e328332e672
- Reed, M. D., Stern, R. C., O’Riordan, M. A., Blumer, J. L. (2001). The Pharmacokinetics of Colistin in Patients with Cystic Fibrosis. The Journal of Clinical Pharmacology, 41 (6), 645–654. doi: http://doi.org/10.1177/00912700122010537
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Roman Sachuk, Yaroslav Stravskyy, Bogdan Gutyj, Tetiana Velesyk, Orest Katsaraba, Sergii Zhyhaliuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
